tbuckley/cabot-search huggingface dataset:
Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy—Reply
Authors: Carlo Greco, Zvi Fuks
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
Authors: Jasmin Jo, Joseph Donahue, Guneet Sarai, Gina Petroni, David Schiff
Journal: Neuro-Oncology (2021)

Venous thromboembolism (VTE) occurs in up to 30% of patients with high-grade glioma (HGG). Concern for increased risk of intracranial hemorrhage (ICH) with therapeutic anticoagulation (AC) complicates VTE treatment. Some retrospective studies have reported an increased risk of ICH associated with therapeutic AC; however, effective alternatives to AC are lacking. The aim of our study is to assess the risk of ICH in HGG patients with VTE on low molecular weight heparin (LMWH).We performed a retrospective matched cohort study of HGG patients from January 2005 to August 2016. Blinded review of neuroimaging for ICH was performed. For analysis of the primary endpoint, estimates of cumulative incidence (CI) of ICH were calculated using competing risk analysis with death as competing risk; significance testing was performed using the Gray's test. Median survival was estimated using the Kaplan-Meier method.Two hundred twenty patients were included, 88 (40%) with VTE treated with LMWH, 22 (10%) with VTE, not on AC, and 110 (50%) without VTE. A total of 43 measurable ICH was recorded: 19 (26%) in LMWH, 3 (14%) in VTE not on AC, and 21 (19%) in non-VTE cohort. No significant difference was observed in the 1-year CI of ICH in the LMWH cohort and non-AC with VTE group (17% vs 9%; Gray's test, P = .36). Among patients without VTE, the 1-year CI of ICH was 13%. Median survival was similar among all 3 cohorts.Our data suggest that therapeutic LMWH is not associated with substantially increased risk of ICH in HGG patients.
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial
Authors: Mona Bafadhel, Neil Barnes, Stephen C. Bourke, Chris Compton, Gerard J. Criner, Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, Benjamin Hartley, C. Elaine Jones, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Robert Wise, Dave Singh
Journal: European Respiratory Journal (2021)

<b>This <i>post hoc</i> analysis of the IMPACT trial demonstrated that a single blood eosinophil count measurement is sufficient to predict a beneficial response to inhaled corticosteroids in patients with symptomatic COPD and a history of exacerbations</b>https://bit.ly/3wgeDCU
Prognostic Value of Serum Potassium Level after Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction
Authors: Kakefuda Yuki, Satoh Akira, Hoshi Tomoya, Harunari Tomohiko, Watabe Hiroaki, Nishina Hidetaka, Takeyasu Noriyuki, Noguchi Yuichi, Aonuma Kazutaka
Journal: Circulation (2014)
Medical encounters at community-based physical activity events (parkrun) in the UK
Authors: Charles R Pedlar, Kyriaki Myrissa, Megan Barry, Iman G Khwaja, Andrew J Simpkin, John Newell, Carl Scarrott, Greg P Whyte, Courtney Kipps, Aaron L Baggish
Journal: British Journal of Sports Medicine (2021)

To determine the incidence, clinical correlates and exposure risk of medical encounters during community-based physical activity events in the UK.An analysis of medical data from weekly, community-based physical activity events (parkrun) at 702 UK locations over a 6-year period (29 476 294 participations between 2014 and 2019) was conducted in order to define the incidence and clinical correlates of serious life-threatening, non-life-threatening and fatal medical encounters.84 serious life-threatening encounters (overall incidence rate=0.26/100 000 participations) occurred including 18 fatalities (0.056/100 000 participations). Statistical modelling revealed that the probabilities of serious life-threatening encounters were exceptionally low, however, male sex, increasing age, slower personal best parkrun time and less prior running engagement/experience (average number of runs per year and number of years as a parkrun participant) were associated with increased probability of serious life-threatening encounters. These were largely accounted for by cardiac arrest (48/84, 57%) and acute coronary syndromes (20/84, 24%). Non-life-threatening medical encounters were mainly attributed to tripping or falling, with a reported incidence of 39.2/100 000 participations.Serious life-threatening and fatal medical encounters associated with parkrun participation are extremely rare. In the context of a global public health crisis due to inactivity, this finding underscores the safety and corollary public health value of community running/walking events as a strategy to promote physical activity.
Impact of Psychological Distress on Treatment Timeliness in Oncology Patients at a Safety-Net Hospital
Authors: Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, An-Lin Cheng
Journal: Journal of the National Comprehensive Cancer Network (2021)

Background: Psychological distress is common in patients with cancer. Distress can affect patients’ engagement with treatment. We examined the relationship between psychological distress and treatment timeliness in a sample of adult oncology patients at a safety-net hospital. Methods: A retrospective review was conducted of all patients screened for distress at a first outpatient oncology visit between March 1, 2014, and December 31, 2015 (n=500). The analytic sample (n=96) included patients with a new cancer diagnosis and a curative-intent treatment plan for lymphoma (stage I–IV), solid tumor malignancy (stage I–III), or head and neck cancer (stage I–IVb). Distress was measured using the Hospital Anxiety and Depression Scale. Using Poisson regression, we determined the effects of depression and anxiety on treatment timeliness. Patient age, sex, race/ethnicity, insurance type, cancer site, and cancer stage were included as covariates. Results: Mean patient age was 54 years. The median treatment initiation interval was 28 days. Clinically significant anxiety was present in 34% of the sample, and clinically significant depression in 15%. Greater symptom severity in both anxiety and depression were associated with a longer treatment initiation interval after controlling for demographics and disease factors. The average days to treatment (DTT) was 4 days longer for patients with elevated anxiety scores and for those with elevated depression scores compared with those without. Overall survival was not associated with anxiety, depression, or DTT. Conclusions: In this safety-net patient sample, greater psychological distress was associated with slower time to treatment. As of writing, this is a new finding in the literature, and as such, replication studies utilizing diverse samples and distress measurement tools are needed.
Richard Christopher David Greenhall
Authors: Charles Warlow, Kevin Talbot
Journal: BMJ (2021)

Richard Christopher David Greenhall devoted the whole of his professional life as a neurologist to working exclusively in the NHS. Never one for pushing himself forward, he was the sort of full time consultant who provides the rock on which the NHS stands, totally dedicated to his clinical service and to his patients.

Richard was a Birmingham boy of Welsh heritage who after leaving King Edward’s School went up to Cambridge in 1962, initially to read natural sciences, although he soon switched to medicine. After clinical training at St Thomas’ Hospital in London, and junior hospital doctor posts in Oxford, Bristol, and London, he started training in neurology under Bryan Matthews in Oxford. Completing his DM thesis in 1975, he flirted …
未熟樹状細胞による同族性CD8+T細胞の欠失: パーフォリン,グランザイムA,TREM-1およびTLR7の新しい役割
Authors: Zangi Lior, Klionsky Yael Zlotnikov, Yarimi Liran, Bachar-Lustig Esther, Eidelstein Yaki, Shezen Elias, Hagin David, Ito Yumi, Takai Toshiyuki, Reich-Zeliger Shlomit, Lask Assaf, Milstein Oren, Jung Steffen, Shinder Vera, Reisner Yair
Journal: Blood (2012)
Atypical lymphocytosis due to <scp>CD8</scp>‐positive <scp>T</scp>‐cell expansion in unsuspected <scp>HIV</scp> infection
Authors: Katrina Parsons, Yezenash Ayalew, Celia Jackson, Mike Leach, Barbara J. Bain
Journal: American Journal of Hematology (2021)

A man in his sixth decade presented to his General Practitioner with a several week history of myalgia and generalized malaise. His blood count was notable for a leukocytosis with a lymphocyte count of 24 × 109/L but was otherwise normal. A peripheral blood film demonstrated smear cells and numerous atypical lymphocytes including medium to large lymphocytes with bilobed or convoluted nuclei, and large granular lymphocytes, some of which were unusually large and also had irregular nuclei; the atypical lymphocytes showed a varying degree of cytoplasmic basophilia, sometimes peripheral (images ×100 objective). Flow cytometric immunophenotyping showed the lymphocytosis to be due to CD8-positive HLA-DR-positive activated T cells, showing partial loss of CD7. On the basis of these findings a virology screen was recommended and was positive for human immunodeficiency virus (HIV) antibody/antigen by a chemiluminescent microparticle immunoassay. The HIV avidity index was less than 40%, which would be consistent with HIV infection acquired within the previous 3–4 months. The HIV RNA viral load at log 6 copies/ml was identified. In addition, IgM and IgG antibodies to cytomegalovirus (CMV) were also detected, indicating recent infection. It is not possible to be certain in this patient if the atypical lymphocytes were the result of CMV or HIV infection, though co-infection might be synergistic. Advanced HIV infection is characterized by lymphopenia but in the early stages there can be lymphocytosis with an increase in activated CD8-positive T cells. The detection of atypical lymphocytes is an indication for a broad viral screen including not only Epstein–Barr virus but also HIV and CMV and, in some clinical settings, dengue virus. Toxoplasmosis and, in children, pertussis should also be remembered. A detailed clinical history is often not available to laboratory staff, who must remain alert to a wide range of diagnostic possibilities. The detection of HIV infection is of particular importance given the therapeutic and other implications of this diagnosis. The authors declare no conflict of interest.
P-110 Is dexamethasone necessary as a prophylactic antiemetic prior to gemcitabine plus nab-paclitaxel therapy?
Authors: S. Murata, M. Takeno, H. Imaoka, K. Morishita, J. Tauchi, H. Suzuki, T. Kawasaki, H. Eguchi, K. Goda, K. Hayashi, T. Otsuru, T. Shibuki, K. Watanabe, S. Miyazawa, M. Sasaki, Y. Hashimoto, S. Mitsunaga, M. Ikeda
Journal: Annals of Oncology (2021)
Experience with cultured thymus tissue in 105 children
Authors: M. Louise Markert, Stephanie E. Gupton, Elizabeth A. McCarthy
Journal: Journal of Allergy and Clinical Immunology (2021)

Currently, there are no approved therapies to treat congenital athymia, a condition of immune deficiency resulting in high early mortality due to infection and immune dysregulation. Multiple syndromic conditions, such as complete DiGeorge syndrome, 22q11.2 deletion syndrome, CHARGE (coloboma, heart defects, choanal atresia, growth or mental retardation, genital hypoplasia, and ear anomalies and/or deafness) syndrome, diabetic embryopathy, other genetic variants, and FOXN1 deficiency, are associated with congenital athymia.Our aims were to study 105 patients treated with cultured thymus tissue (CTT), and in this report, to focus on the outcomes of 95 patients with treatment-naive congenital athymia.A total of 10 prospective, single-arm open-label studies with patient enrollment from 1993 to 2020 form the basis of this data set. Patients were tested after administration of CTT for T-cell development; all adverse events and infections were recorded.A total of 105 patients were enrolled and received CTT (the full analysis set). Of those patients, 10 had diagnoses other than congenital athymia and/or received prior treatments. Of those 105 patients, 95 patients with treatment-naive congenital athymia were included in the efficacy analysis set (EAS). The Kaplan-Meier estimated survival rates at year 1 and year 2 after administration of CTT in the EAS were 77% (95% CI = 0.670-0.844) and 76% (95% CI = 0.657-0.834), respectively. In all, 21 patients died in the first year before developing naive T cells and 1 died in the second year after receipt of CTT; 3 subsequent deaths were not related to immunodeficiency. A few patients developed alopecia, autoimmune hepatitis, psoriasis, and psoriatic arthritis after year 1. The rates of infections, autologous graft-versus-host-disease manifestations, and autoimmune cytopenias all decreased approximately 1 year after administration of CTT.Treatment with CTT led to development of naive T cells with a 1-year survival rate of 77% and a median follow-up time of 7.6 years. Immune reconstitution sufficient to prevent infections and support survival typically develops 6 to12 months after administration of CTT.
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update
Authors: Andrew M Veitch, Franco Radaelli, Raza Alikhan, Jean Marc Dumonceau, Diane Eaton, Jo Jerrome, Will Lester, David Nylander, Mo Thoufeeq, Geoffroy Vanbiervliet, James R Wilkinson, Jeanin E Van Hooft
Journal: Gut (2021)

This is a collaboration between the British Society of Gastroenterology (BSG) and the European Society of Gastrointestinal Endoscopy (ESGE), and is a scheduled update of their 2016 guideline on endoscopy in patients on antiplatelet or anticoagulant therapy. The guideline development committee included representatives from the British Society of Haematology, the British Cardiovascular Intervention Society, and two patient representatives from the charities Anticoagulation UK and Thrombosis UK, as well as gastroenterologists. The process conformed to AGREE II principles and the quality of evidence and strength of recommendations were derived using GRADE methodology. Prior to submission for publication, consultation was made with all member societies of ESGE, including BSG. Evidence-based revisions have been made to the risk categories for endoscopic procedures, and to the categories for risks of thrombosis. In particular a more detailed risk analysis for atrial fibrillation has been employed, and the recommendations for direct oral anticoagulants have been strengthened in light of trial data published since the previous version. A section has been added on the management of patients presenting with acute GI haemorrhage. Important patient considerations are highlighted. Recommendations are based on the risk balance between thrombosis and haemorrhage in given situations.
25907 Actinic keratosis in Colombia: First approaches
Authors: David A. Castillo Molina, Jesus D. Fierro Lozada, Diana Quintero Estupiñan, Maria J. Carroll-Patiño, Mariana Reyes Rey, Paula A. Chacón Jaramillo, Nanis Ramirez Herrera, Paula C. Rubiano Mojica, Nelson José Alvis-Zakzuk, Gabriela Bula Galán, David E. Castillo Saavedra
Journal: Journal of the American Academy of Dermatology (2021)
Abstract 3077: Does Baseline Atrial Rhythm Predict Long Term Clinical Response To Cardiac Resynchronization Therapy?
Authors: christophe leclercq, Arnaud Rozier, Christophe Crocq, Olivier Césari, Erwan Donal, Christian de Place, Philippe Mabo, Claude Daubert
Journal: Circulation (2007)

Background: Cardiac resynchronization therapy (CRT) is a recommended treatment in patients (pts) with advanced heart failure (HF), left ventricular systolic dysfunction, wide QRS and stable sinus r...
Fundamentals of Public Health — A New Perspective Series
Authors: Barry R. Bloom, Debra Malina, Genevra Pittman, Stephen Morrissey, Eric J. Rubin
Journal: New England Journal of Medicine (2021)

The Covid-19 pandemic has awakened many physicians to the value of viewing wellness and disease through the lens of public health as well as that of clinical medicine. To help foster such a reframing, the Journal is launching a new Perspective series.
Community-based point-of-care hepatitis C testing and general practitioner initiated direct-acting antiviral therapy in Yangon, Myanmar (CT2 study)
Authors: Bridget Draper, Win Lei Yee, Alisa Pedrana, Jess Howell, Hla Htay, Win Naing, Khin Sanda Aung, Nwe Nwe, Sonjelle Shilton, Jessica Markby, Khin Pyone Kyi, Margaret Hellard
Journal: Journal of Hepatology (2020)
Mitochondrial Metabolism Targeted Nanoplatform for Efficient Triple‐Negative Breast Cancer Combination Therapy
Authors: Lu Lu, Genhua Liu, Chuanchuan Lin, Ke Li, Tingting He, Jixi Zhang, Zhong Luo, Kaiyong Cai
Journal: Advanced Healthcare Materials (2021)

Abstract Tumor reprogram pathway of mitochondrial metabolism is an emerging approach for malignant tumor treatment, such as triple‐negative breast cancer. In this study, a tumor/mitochondria cascaded targeting, adenosine‐triphosphate (ATP) responsive nanocarrier of zeolitic imidazolate framework‐90 (ZIF‐90) for breast cancer combination therapy is reported. Atovaquone (AVO) and hemin are loaded into ZIF‐90, then a peptide iRGD with tumor‐targeting ability is modified on the ZIF‐90 nanoplatform. Hemin can specifically degrade BTB and CNC homology1 (BACH1), resulting in the changes of mitochondrial metabolism, and AVO acts as the inhibitor of the electron transport chain (ETC). The degradation of BACH1 using hemin can effectively improve the anti‐tumor efficiency of mitochondrial metabolism inhibitor AVO, by increasing dependency on mitochondrial respiration. This nanoplatform displays both tumor‐targeting and mitochondria‐targeting capacity with high level of ATP responsive drug release behavior. The specific characteristic of mitochondria‐targeting ability of this nanoplatform can increase the accumulation of AVO in the mitochondria, and in turn, can effectively improve the inhibition of the ETC. Both in vitro and in vivo results reveal that this composite nanocarrier has excellent tumor inhibition ability with limited side effects. Accordingly, this study provides an attractive strategy in the mitochondrial metabolism for cancer targeted therapy.
Effect of didecyl dimethyl ammonium chloride-impregnated washcloth wipe whole-body bathing on catheter-related blood stream infections and central venous line-associated infections in adult intensive care units
Authors: Fabian von Dehn, Nico T. Mutters, Vanessa M. Eichel, Uta Merle, Thorsten Brenner, Michael Nafe, Anja Sander, Martin Wolkewitz, Uwe Frank
Journal: Clinical Microbiology and Infection (2021)
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events
Authors: Elie Rassy, Barbara Pistilli, Caroline Robert
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Avoidant Restrictive Food Intake Disorder Prevalent Among Patients With Inflammatory Bowel Disease
Authors: Emily Yelencich, Emily Truong, Adrianne M. Widaman, Giselle Pignotti, Liu Yang, Yejoo Jeon, Andrew T. Weber, Rishabh Shah, Janelle Smith, Jenny S. Sauk, Berkeley N. Limketkai
Journal: Clinical Gastroenterology and Hepatology (2021)

Patients with inflammatory bowel disease (IBD) alter their dietary behaviors to reduce disease-related symptoms, avoid feared food triggers, and control inflammation. This study aimed to estimate the prevalence of avoidant/restrictive food intake disorder (ARFID), evaluate risk factors, and examine the association with risk of malnutrition in patients with IBD.This cross-sectional study recruited adult patients with IBD from an ambulatory clinic. ARFID risk was measured using the Nine-Item ARFID Screen. Nutritional risk was measured with the Patient Generated-Subjective Global Assessment. Logistic regression models were used to evaluate the association between clinical characteristics and a positive ARFID risk screen. Patient demographics, disease characteristics, and medical history were abstracted from medical records.Of the 161 participants (Crohn's disease, 45.3%; ulcerative colitis, 51.6%; IBD-unclassified, 3.1%), 28 (17%) had a positive ARFID risk score (≥24). Most participants (92%) reported avoiding 1 or more foods while having active symptoms, and 74% continued to avoid 1 or more foods even in the absence of symptoms. Active symptoms (odds ratio, 5.35; 95% confidence interval, 1.91-15.01) and inflammation (odds ratio, 3.31; 95% confidence interval, 1.06-10.29) were significantly associated with positive ARFID risk. Patients with a positive ARFID risk screen were significantly more likely to be at risk for malnutrition (60.7% vs 15.8%; P < .01).Avoidant eating behaviors are common in IBD patients, even when in clinical remission. Patients who exhibit active symptoms and/or inflammation should be screened for ARFID risk, with referrals to registered dietitians to help monitor and address disordered eating behaviors and malnutrition risk.